Trial reportDrug design, development and therapy2025
Effect of Stellate Ganglion Block on Preventing Atrial Fibrillation After Esophagectomy: A Double-Blind Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Stellate ganglion block achieves remission of recurrent head-and-neck plaque psoriasis: A case report.The Journal of international medical research · 2026Article
- Effects of Preoperative Stellate Ganglion Block on Postoperative Sore Throat and Hoarseness in Patients Undergoing Double-Lumen Endobronchial Intubation: Protocol for a Prospective Randomized Controlled Trial.Journal of pain research · 2026Article
- The potential role of stellate ganglion block in impacting the central and peripheral systems: a narrative review.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative atrial fibrillation (POAF) is a common complication after esophagectomy and is associated with adverse outcomes. This study investigated whether preoperative stellate ganglion block (SGB) could reduce the incidence of POAF and improve postoperative recovery. Methods: In this single-center, randomized, double-blind, placebo-controlled trial, 100 patients undergoing esophagectomy were randomly assigned to receive ultrasound-guided right-sided SGB with 7 mL of either 0.5% ropivacaine (SGB group) or normal saline (control group). The primary outcome was the incidence of POAF within 72 hours postoperatively. Secondary outcomes included the timing and duration of POAF, heart rate variability, other arrhythmias, sufentanil consumption, pain scores, vital signs, sleep quality, gastrointestinal recovery, length of hospital stay, complications and mortality. Results: The incidence of POAF was 10% in both groups (OR = 1.0, 95% CI: 0.27-3.69, Conclusion: Although SGB did not reduce the incidence of POAF, it was associated with improved postoperative recovery. These findings suggest that SGB may serve as a beneficial adjunct to optimize recovery following esophagectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.